8-K: Senti Bio Reports Promising Initial Clinical Data for SENTI-202 in Relapsed/Refractory AML

Senti Biosciences announced encouraging initial clinical data from its Phase 1 trial of SENTI-202, showing complete remission in two out of three relapsed/refractory AML patients at the first dose level.

Summary

• Senti Biosciences has released initial clinical data for SENTI-202, a novel NK cell therapy for acute myeloid leukemia (AML).
• The data comes from the Phase 1 clinical trial, where the first dose level of 1 billion CAR+ NK cells was tested on three relapsed/refractory AML patients.
• Two out of three patients achieved a complete remission (CR) with measurable residual disease (MRD) negativity.
• One of the patients had adverse-risk genetics and had relapsed after intensive chemotherapy and a prior hematopoietic cell transplant (HCT).
• The second patient had a FLT3 mutation and relapsed after intensive chemotherapy and a FLT3 inhibitor.
• The third patient did not respond to the treatment and had progressive disease.
• SENTI-202 was generally well-tolerated, with side effects consistent with other NK cell therapies and lymphodepleting chemotherapy.
• The company is actively enrolling patients in the second dose level cohort at 1.5 billion CAR+ NK cells.
• The company plans to transition from Phase 1 to a pivotal study.
• SENTI-202 is designed with logic gating to target CD33 and FLT3 while sparing healthy cells via the EMCN target.

Sentiment

Score: 8

Explanation: The document presents very positive initial clinical data for SENTI-202, with a high rate of complete remission in a difficult-to-treat patient population. The safety profile also appears favorable. However, it is still early data and the long term durability is unknown.

Positives

• The initial clinical data shows promising efficacy with two out of three patients achieving complete remission.
• SENTI-202 appears to be well-tolerated, with a safety profile consistent with other NK cell therapies.
• The logic gating design of SENTI-202 aims to improve safety by sparing healthy cells.
• The company is progressing with dose escalation and plans to move to a pivotal study.
• The detection of the SENTI-202 transgene in the peripheral blood indicates the therapy is reaching its target.

Negatives

• One out of three patients did not respond to the treatment and had progressive disease.
• The study is still in its early stages, and more data is needed to confirm the efficacy and safety of SENTI-202.
• The study is limited to a small number of patients.

Risks

• The clinical trial is still ongoing, and the results may change as more data becomes available.
• The long-term durability of the responses is not yet known.
• There is a risk of adverse events associated with the treatment.
• The company may face challenges in manufacturing and scaling up production of SENTI-202.
• The company is dependent on third parties for development and manufacture of product candidates.

Future Outlook

The company plans to transition from the Phase 1 trial to a pivotal study and expects to release durability data in 2025. They also expect the first patient to be enrolled in the SENTI-301A trial in China in Q4 2024.

Management Comments

• Senti Biosciences CEO, Tim Lu, stated that SENTI-202 is designed to integrate validated mechanisms into one solution, engineered to solve key outstanding problems in AML.
• Kanya Rajangam, President, Head of R&D and CMO, highlighted the early efficacy signals noted at the first dose level.

Industry Context

The development of SENTI-202 addresses the unmet need for effective therapies in relapsed/refractory AML, a disease with poor prognosis and limited treatment options. The use of logic-gated CAR-NK cells represents an innovative approach to improve both efficacy and safety compared to traditional therapies.

Comparison to Industry Standards

• Current standard treatments for relapsed/refractory AML, such as salvage chemotherapy and targeted agents, achieve complete remission in only 20-30% of patients.
• The reported complete remission rate of 66% (2 out of 3 patients) at the first dose level of SENTI-202 is a promising early result.
• Other CAR-T cell therapies have shown efficacy in hematological malignancies, but they often come with significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity.
• SENTI-202's tolerability profile appears favorable compared to some CAR-T therapies, although more data is needed to confirm this.
• Companies like Kite Pharma and Novartis have developed CAR-T therapies for blood cancers, but SENTI-202's NK cell approach and logic gating technology offer a potentially differentiated approach.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data.
• Patients with relapsed/refractory AML may have a new treatment option.
• Employees may be motivated by the positive results and the potential to bring a new therapy to market.
• The company's partners may be encouraged by the progress of the SENTI-202 program.

Next Steps

• Continue enrollment in the second dose level cohort of the Phase 1 trial.
• Transition from Phase 1 to a pivotal study.
• Release durability data in 2025.
• Enroll the first patient in the SENTI-301A trial in China in Q4 2024.

Key Dates

Keywords

SENTI-202, AML, Acute Myeloid Leukemia, NK Cell Therapy, CAR-NK, Clinical Trial, Complete Remission, MRD, Logic Gating, CD33, FLT3, EMCN